A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol [SUBSTUDY OF 700216591]

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
Indications Carcinoma; Early breast cancer; HER2 positive breast cancer
Focus Biomarker; Pharmacodynamics; Therapeutic Use
Acronyms ADAPT-HER2+HR-

Most Recent Events

27 Mar 2023 Planned End Date changed from 1 Aug 2020 to 1 Oct 2024.
23 Mar 2023 Status changed to recruiting.
28 Nov 2022 Results identifying associations of biological signatures and stromal tumor infiltrating lymphocytes with pathological complete response and survival, published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight